Visionary Wealth Advisors’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Visionary Wealth Advisors’s Portfolio ONCT Stock Details ONCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-505	Closed	-$10K	–	477
2022 Q4	$10K	Hold	505	–	–	﹤0.01%	422
2022 Q3	$9K	Hold	505	–	–	﹤0.01%	398
2022 Q2	$11K	Hold	505	–	–	﹤0.01%	434
2022 Q1	$14K	Buy	+505	New	+$18.4K	﹤0.01%	436
2021 Q4	–	Sell	-925	Closed	-$77K	–	399
2021 Q3	$77K	Buy	925 +15	+2%	+$1.24K	0.01%	305
2021 Q2	$86K	Buy	+910	New	+$108K	0.01%	327

Other funds holding ONCT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BIT Capital Berlin, Germany $2.07B AUM 157.17% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

QPW

Quantum Private Wealth Tampa, Florida $324M AUM 37.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BJL

Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Visionary Wealth Advisors's ONCT Position: Q1 2023 in Review

Visionary Wealth Advisors sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q1 2023, closing a stake of 505 shares — an estimated $10K sold.

Visionary Wealth Advisors first reported a position in ONCT in Q2 2021 and held it in 6 quarters. The position peaked at $86K in Q2 2021. 54 funds tracked by Wall St. Rank hold ONCT as of Q1 2023.

Visionary Wealth Advisors reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
Visionary Wealth Advisors sold 505 Oncternal Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $10K.
Visionary Wealth Advisors first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2021 and held it in 6 quarters.
Visionary Wealth Advisors's Oncternal Therapeutics, Inc. Common Stock position peaked at $86K in Q2 2021.
54 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q1 2023.

Based on Visionary Wealth Advisors's 13F filing for Q1 2023, filed 15 May 2023.